Clinical Trial Update: Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating adjuvant radiotherapy with sintilimab versus transarterial chemoembolization for hepatocellular carcinoma is currently recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Tyvyt (Sintilimab) (Sintilimab)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Hepatocellular Carcinoma (HCC), Radiotherapy, Adjuvant | Phase 3 | Status: RECRUITING